Physician profile
Mark E Decheck
NPI 1134129380
$6,383.18
in general payments reported to CMS, 2019-2025
42 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $565 · 2021: $1,099 · 2022: $665 · 2023: $1,136 · 2024: $1,354 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,953.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.19 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $543.64 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $493.49 | 2019-2025 | Myrbetriq, Veozah |
| Novo Nordisk INC | $483.57 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $458.71 | 2022-2024 | Eliquis, Camzyos |
| Pfizer INC. | $383.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $366.54 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $250.98 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.99 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.74 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $182.17 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $153.95 | 2019-2021 | |
| Allergan, INC. | $147.11 | 2019-2020 | |
| Amgen INC. | $144.12 | 2019-2024 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $139.19 | 2020-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $134.75 | 2021 | |
| Almatica Pharma LLC | $132.09 | 2024-2025 | Loreev Xr |
| Exact Sciences Corporation | $130.54 | 2023-2025 | Cologuard Collection Kit |
| Ani Pharmaceuticals, INC. | $114.30 | 2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $99.56 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sunovion Pharmaceuticals INC. | $97.96 | 2020-2021 | |
| Amarin Pharma, INC. | $81.17 | 2020-2022 | |
| Lundbeck LLC | $80.37 | 2024 | Rexulti |
| Corium, LLC | $80.01 | 2022-2023 | Adlarity |
| Idorsia Pharmaceuticals US INC | $74.17 | 2022-2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $73.58 | 2024 | Nuzyra |
| Smith+Nephew, INC. | $60.65 | 2024 | Collagenase Santyl, Grafix Pl |
| Takeda Pharmaceuticals U.S.A., INC. | $40.67 | 2021-2022 | |
| Esperion Therapeutics, INC. | $36.92 | 2020-2021 | |
| Evoke Pharma, INC. | $35.16 | 2021-2024 | |
| Dexcom, INC. | $34.56 | 2023-2025 | Dexcom G6 Transmitter |
| Sun Pharmaceutical Industries INC. | $31.51 | 2024 | |
| Ge Healthcare | $29.30 | 2023 | |
| Sanofi Pasteur INC. | $29.30 | 2020-2023 | |
| Vanda Pharmaceuticals INC. | $20.00 | 2024 | Fanapt |
| Actelion Pharmaceuticals US, INC. | $19.95 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.90 | 2021 | |
| Melinta Therapeutics, LLC | $15.32 | 2024 | Orbactiv, Kimyrsa |
| Ibsa Pharma INC. | $15.31 | 2024 | Licart, Tirosint |
| Acorda Therapeutics, INC | $14.64 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.65 | 2021 | |
| Eisai INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Decheck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.